Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AACER: Cetuximab with Chemoradiotherapy in High-Risk Head and Neck Cancer
NCT00875849Phase 2Completed
- Sponsor
- Centre Antoine Lacassagne
- Start
- Mar 2008
- Primary completion
- Feb 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Centre Antoine Lacassagne. Primary endpoint: Disease-free survival at 2 years. Started Mar 2008; status: completed.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00875849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00875849.